期刊论文详细信息
BMC Medical Genomics
Protein and microRNA biomarkers from lavage, urine, and serum in military personnel evaluated for dyspnea
Richard Gelinas2  Ji-Hoon Cho2  Richard D Smith1  Joshua N Adkins1  Andrew J Skabelund3  Michael J Morris3  Karl K Weitz1  Carrie D Nicora1  Heather M Brewer1  Joseph N Brown1 
[1] Biological Sciences Division, Pacific Northwest National Laboratories, Richland, WA 99354, USA;Institute for Systems Biology, Seattle, WA 98109, USA;San Antonio Military Medical Center, Fort Sam Houston, San Antonio, TX 78234, USA
关键词: MicroRNAs;    Proteomics;    Urine;    Serum;    Lavage fluid;    Biomarkers;    Dyspnea;   
Others  :  1090338
DOI  :  10.1186/1755-8794-7-58
 received in 2014-05-06, accepted in 2014-09-29,  发布年份 2014
PDF
【 摘 要 】

Background

We have identified candidate protein and microRNA (miRNA) biomarkers for dyspnea by studying serum, lavage fluid, and urine from military personnel who reported serious respiratory symptoms after they were deployed to Iraq or Afghanistan.

Methods

Forty-seven soldiers with the complaint of dyspnea who enrolled in the STudy of Active Duty Military Personnel for Environmental Dust Exposure (STAMPEDE) underwent comprehensive pulmonary evaluations at the San Antonio Military Medical Center. The evaluation included fiber-optic bronchoscopy with bronchoalveolar lavage. The clinical findings from the STAMPEDE subjects pointed to seven general underlying diagnoses or findings including airway hyperreactivity, asthma, low diffusivity of carbon monoxide, and abnormal cell counts. The largest category was undiagnosed. As an exploratory study, not a classification study, we profiled proteins or miRNAs in lavage fluid, serum, or urine in this group to look for any underlying molecular patterns that might lead to biomarkers. Proteins in lavage fluid and urine were identified by accurate mass tag (database-driven) proteomics methods while miRNAs were profiled by a hybridization assay applied to serum, urine, and lavage fluid.

Results

Over seventy differentially expressed proteins were reliably identified both from lavage and from urine in forty-eight dyspnea subjects compared to fifteen controls with no known lung disorder. Six of these proteins were detected both in urine and lavage. One group of subjects was distinguished from controls by expressing a characteristic group of proteins. A related group of dyspnea subjects expressed a unique group of miRNAs that included one miRNA that was differentially overexpressed in all three fluids studied. The levels of several miRNAs also showed modest but direct associations with several standard clinical measures of lung health such as forced vital capacity or gas exchange efficiency.

Conclusions

Candidate proteins and miRNAs associated with the general diagnosis of dyspnea have been identified in subjects with differing medical diagnoses. Since these markers can be measured in readily obtained clinical samples, further studies are possible that test the value of these findings in more formal classification or case–control studies in much larger cohorts of subjects with specific lung diseases such as asthma, emphysema, or some other well-defined lung disease.

【 授权许可】

   
2014 Brown et al.; licensee BioMed Central Ltd.

【 预 览 】
附件列表
Files Size Format View
20150128160206680.pdf 3460KB PDF download
Figure 7. 195KB Image download
Figure 6. 81KB Image download
Figure 5. 115KB Image download
Figure 4. 186KB Image download
Figure 3. 68KB Image download
Figure 2. 174KB Image download
Figure 1. 73KB Image download
【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】
  • [1]Morris M, Dodson D, Lucero P, Haislip G, Gallup R, Nicholson K, Zacher L: Study of active duty military for pulmonary disease related to environmental deployment exposures (STAMPEDE). Am J Respir Crit Care Med 2014, 190:77-84.
  • [2]Maisel A, Mueller C, Nowak R, Peacock W, Landsberg J, Ponikowski P, Mockel M, Hogan C, Wu A, Richards M, Clopton P, Filippatos G, Di Somma S, Anand I, Ng L, Daniels L, Neath S, Christenson R, Potocki M, McCord J, Terracciano G, Kremastinos D, Hartmann O, von Haehling S, Bergmann A, Morgenthaler N, Anker S: Mid-region Pro-hormone markers for diagnosis and prognosis in acute DyspneaResults from the BACH (biomarkers in acute heart failure) trial. J Am Coll Cardiol 2010, 55:2062-2076.
  • [3]Szefler S, Wenzel S, Brown R, Erzurum S, Fahy J, Hamilton R, Hunt J, Kita H, Liu A, Panettieri R, Schleimer R, Minnicozzi M: Asthma outcomes: biomarkers. J Allergy Clin Immunol 2012, 129:S9-S23.
  • [4]Erzurum S, Gaston B: Biomarkers in asthma: a real hope to better manage asthma. Clin Chest Med 2012, 33:459-471.
  • [5]Sircar G, Saha B, Bhattacharya S, Saha S: Allergic asthma biomarkers using systems approaches. Front Genet 2013, 4:308. doi:10.3389/fgene.2013.00308; PMCID: PMC3884215
  • [6]Ezzie M, Crawford M, Cho J, Orellana R, Zhang S, Gelinas R, Batte K, Yu L, Nuovo G, Galas D, Diaz P, Wang K, Nana-Sinkam P: Gene expression networks in COPD: microRNA and mRNA regulation. Thorax 2011. doi:10.1136/thoraxjnl-2011-200089
  • [7]Pinto-Plata V, Mullerova H, Casanova C, de Torres J, Corado H, Varo N, Cordoba E, Baz R, Cortopasi F, Divo M, Kelly E, Celli B: Serum biomarkers in COPD survivors and controls. Longitudinal analysis. Am J Respir Crit Care Med 2012, 185:A4507.
  • [8]Cho J, Gelinas R, Wang K, Etheridge A, Piper M, Batte K, Dakhlallah D, Price J, Bornman D, Zhang S, Marsh C, Galas D: Systems biology of interstitial lung diseases: integration of mRNA and microRNA expression changes. BMC Med Genet 2011, 4:8.
  • [9]Park M, Vittinghoff E, Liu K, Shlipak M, Hsu C: Urine biomarkers neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) have different patterns in heart failure exacerbation. Biomark Insights 2013, 8:15.
  • [10]Parikh C, Butrymowicz I, Yu A, Chinchilli V, Park M, Hsu C, Reeves W, Devarajan P, Kimmel P, Siew E, Liu K: Urine stability studies for novel biomarkers of acute kidney injury. Am J Kidney Dis 2014, 63:567-572.
  • [11]Roobol MJ, Haese A, Bjartell A: Tumour markers in prostate cancer III: biomarkers in urine. Acta Oncol 2011, 50:85-89.
  • [12]Ploussard G, de la Taille A: Urine biomarkers in prostate cancer. Nat Rev Urol 2010, 7:101-109.
  • [13]Ben-Dov I, Tan Y, Morozov P, Wilson P, Rennert H, Blumenfeld J, Tuschl T: Urine MicroRNA as potential biomarkers of autosomal dominant polycystic kidney disease progression: description of miRNA profiles at baseline. PLoS One 2014, 9:e86856.
  • [14]Maiolica A, Borsotti D, Rappsilber J: Self-made frits for nanoscale columns in proteomics. Proteomics 2005, 5:3847-3850.
  • [15]Kelly RT, Page JS, Luo Q, Moore RJ, Orton DJ, Tang K, Smith R: Chemically etched open tubular and monolithic emitters for nanoelectrospray ionization mass spectrometry. Anal Chem 2006, 78:7796-7801.
  • [16]Zimmer JS, Monroe ME, Qian WJ, Smith R: Advances in proteomics data analysis and display using an accurate mass and time tag approach. Mass Spectrom Rev 2006, 25:450-482.
  • [17]Stanley JR, Adkins JN, Slysz GW, Monroe ME, Purvine SO, Karpievitch YV, Anderson GA, Smith RD, Dabney AR: A statistical method for assessing Peptide identification confidence in accurate mass and time tag proteomics. Anal Chem 2011, 83:6135-6140.
  • [18]Jaitly N, Mayampurath A, Littlefield K, Adkins JN, Anderson GA, Smith RD: Decon2LS: an open-source software package for automated processing and visualization of high resolution mass spectrometry data. BMC Bioinform 2009, 10:87. doi:10.1186/1471-2105-10-87 BioMed Central Full Text
  • [19]Monroe ME, Tolić N, Jaitly N, Shaw JL, Adkins JN, Smith RD: VIPER: an advanced software package to support high-throughput LC-MS peptide identification. Bioinformatics 2007, 23:2021-2023. Epub 2007 Jun 1
  • [20]Webb-Robertson BJ, Matzke MM, Jacobs JM, Pounds JG, Waters KM: A statistical selection strategy for normalization procedures in LC-MS proteomics experiments through dataset-dependent ranking of normalization scaling factors. Proteomics 2011, 11:4736-4741.
  • [21]Norbeck A, Monroe M, Adkins J, Smith R: The utility of accurate mass and LC elution time information in the analysis of complex proteomes. J Am Soc Mass Spectrom 2005, 16:1239-1249.
  • [22]Matzke MM, Waters KM, Metz TO, Jacobs JM, Sims AC, Baric RS, Pounds JG, Webb-Robertson BJ: Improved quality control processing of peptide-centric LC-MS proteomics data. Bioinformatics 2011, 27:2866-2872.
  • [23]Huang D, Sherman B, Tan Q, Kir J, Liu D, Bryant D, Guo Y, Stephens R, Baseler M, Lane H, Lempicki R: DAVID bioinformatics resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res 2007, 35(suppl 2):W169-W175.
  • [24]Clough T, Key M, Ott I, Ragg S, Schadow G, Vitek O: Protein quantification in label-free LC-MS experiments. J Proteome Res 2009, 8:5275-5284.
  • [25]Benjamini Y, Hochberg Y: Controlling the false discovery rate - a practical and powerful approach to multiple testing. j Roy Stat Soc B Met 1995, 57:289-300.
  • [26]Team RDC: R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2008.
  • [27]Geiss G, Bumgarner R, Birditt B, Dahl T, Dowidar N, Dunaway D, Fell H, Ferree S, George R, Grogan T, James J, Maysuria M, Mitton J, Oliveri P, Osborn J, Peng T, Ratcliffe A, Webster P, Davidson E, Hood L, Krassen D: Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 2008, 26:317-325.
  • [28]Weber J, Baxter D, Zhang S, Huang D, Huang K, Lee M, Galas D, Wang K: The microRNA spectrum in 12 body fluids. Clin Chem 2010, 2010(56):1733-1741. doi:10.1373/clinchem.2010.147405
  • [29]Waggott D, Chu K, Yin S, Wouters B, Liu F, Boutros P: NanoStringNorm. Bioinformatics 2012, 28:1546-1548.
  • [30]Smyth GK: Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004, 3:1. Article 3
  • [31]Szema AM, Peters MC, Weissinger KM, Gagliano CA, Chen J: New-onset asthma among soldiers serving in Iraq and Afghanistan. Allergy Asthma Proc 2010, 31:67-71. doi:10.2500/aap.2010.31.3383
  • [32]King M, Eisenberg R, Newman J, Tolle J, Harrell F, Nian H, Ninan M, Lambright E, Sheller J, Johnson J, Miller R: Constrictive bronchiolitis in soldiers returing from Iraq and Afghanistan. N Engl J Med 2011, 365:222-230. doi:10.1056/NEJMoa1101388
  • [33]Li XJ, Hayward C, Fong PY, Dominguez M, Hunsucker SW, Lee LW, McLean M, Law S, Butler H, Schirm M, Gingras O, Lamontagne J, Allard R, Chelsky D, Price ND, Lam S, Massion PP, Pass H, Rom WN, Vachani A, Fang KC, Hood L, Kearney P: A blood-based proteomic classifier for the molecular characterization of pulmonary nodules. Sci Transl Med 2013, 5:207ra-142.
  • [34]Fan R, Vermesh O, Srivastava A, Yen B, Qin L, Ahmad H, Kwong G, Liu C, Gould J, Hood L, Heath J: Integrated barcode chips for rapid, multiplexed analysis of proteins in microliter quantities of blood. Nat Biotechnol 2008, 26:1373-1378. doi:10.1038/nbt.1507
  • [35]Dorfmüller P: Pulmonary Hypertension: Pathology. In Pharmacotherapy of Pulmonary Hypertension. Heidelberg: Springer Berlin; 2013:59-75.
  • [36]de Prost N, Parrot A, Cuquemelle E, Picard C, Cadranel J: Immune diffuse alveolar hemorrhage: a retrospective assessment of a diagnostic scale. Lung 2013, 191:559-563.
  • [37]Puxeddu E, Comandini A, Cavalli F, Pezzuto G, D’Ambrosio C, Senis L, Paci M, Curradi G, Sergiacomi G, Saltini C: Iron laden macrophages in idiopathic pulmonary fibrosis: the telltale of occult alveolar hemorrhage? Pulmonary Pharmacol Therapeutics 2014, 28:35-40.
  • [38]Huang H, Yu H, Huang L, Huang HC, Chen R, Lin I, Ou C, Hsu T, Yang K: miRNA-125b regulates TNF-α production in CD14+ neonatal monocytes via post-transcriptional regulation. J Leukoc Biol 2012, 92:171-182.
  • [39]Cohn L, Elias J, Chupp G: Asthma: mechanisms of disease persistence and progression. Annu Rev Immunol 2004, 22:789-815.
  • [40]Broide DH: Immunologic and inflammatory mechanisms that drive asthma progression to remodeling. J Allergy Clin Immunol 2008, 121:560-570.
  • [41]Royce S, Cheng V, Samuel C, Tang M: The regulation of fibrosis in airway remodeling in asthma. Mol Cell Endocrinol 2012, 351:167-175.
  • [42]Pritchard C, Kroh E, Wood B, Arroyo J, Dougherty K, Miyaji M, Tait J, Tewari M: Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prevention Res 2012, 5:492-497. doi:10.1158/1940-6207.capr-11-0370
  • [43]Zhou A, Diao L, Xu H, Xiao Z, Li J, Xhou H, Qu L: β-catenin/LEF1 transactivates the microRNA-371-373 cluster that modulates the Wnt/β-catenin pathway. Oncogene 2012, 31:2968-2978.
  • [44]Hu H, Du L, Nagabayashi G, Seeger R, Gatti R: ATM is down-regulated by N-Myc-regulated microRNA-421. Proc Natl Acad Sci U S A 2010, 107:1506-1511.
  • [45]Hu H, Gatti R: MicroRNAs: new players in the DNA damage response. J Mol Cell Biol 2011, 3:151-158.
  • [46]Hao J, Zhang S, Zhou Y, Liu C, Hu X, Shao C: MicroRNA 421 suppresses DPC4/Smad4 in pancreatic cancer. Biochem Biophys Res Comm 2011, 406:552-557.
  • [47]Zhang X, Cui L, Ye G, Zheng T, Song H, Xia T, Yu X, Xiao B, Le Y, Guo J: Gastric juice microRNA-421 is a new biomarker for screening gastric cancer. Tumor Biol 2012, 33:2349-2355.
  • [48]Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens R, Okamoto A, Yokota J, Tanaka T, Calin G, Liu C, Croce C, Harris C: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9:189-198.
  • [49]Van Pottelberge G, Mestdagh P, Bracke K, Thas O, van Durme Y, Joos G, Vandesompele J, Brusselle G: MicroRNA expression in induced sputum of smokers and patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011, 183:898-906.
  • [50]Wang T, Campbell J, Liu G, LeClerc A, Alekseyev Y, Luo L, Xiao J, Zhang X, Sin D, McWilliams A, Lam S, Spira A, Lenburg M: Bronchial airway microRNA expression associated with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013, 187:A1201.
  • [51]Solberg O, Ostrin E, Love M, Peng J, Bhakta N, Hou L, Nguyen C, Solon M, Nguyen C, Barczak A, Zlock L, Blagev D, Finkbeiner W, Ansel K, Arron J, Erle D, Woodruff P: Airway epithelial miRNA expression is altered in asthma. Am J Respir Crit Care Med 2012, 186:965-974. doi:10.1164/rccm.201201-00170C
  • [52]Wang J, Zhang K-Y, Liu S-M, Sen S: Tumor-associated circulating microRNAs as biomarkers of cancer. Molecules 2014, 19:1912-1938. doi:10.3390/molecules19021912
  • [53]Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, Calabro E, Croce C, Pastorino U, Sozzi G: MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A 2011, 108:3713-3718. doi/10.1073/pnas.1100048108
  • [54]Sheinerman K, Tsivinsky V, Umansky S: Analysis of organ-enriched microRNAs in plasma as an approach to development of universal screening test: feasibility study. J Transl Med 2013, 11:304. doi:10.1186/1479-5876-11-304 BioMed Central Full Text
  • [55]Sah S, McCall M, Eveleigh D, Wilson M, Irizarry R: Performance evaluation of commercial miRNA expression array platforms. BMC Res Notes 2010, 3:80. doi:10.1186/1756-0500-3-80 BioMed Central Full Text
  文献评价指标  
  下载次数:185次 浏览次数:8次